|
Originally published In Press as doi:10.1074/jbc.M000296200 on May 22, 2000
J. Biol. Chem., Vol. 275, Issue 34, 25883-25891, August 25, 2000
Characterization of the Recombinant IKK1/IKK2 Heterodimer
MECHANISMS REGULATING KINASE ACTIVITY*
Q. Khai
Huynh ,
Hymavathi
Boddupalli,
Sharon A.
Rouw,
Carol M.
Koboldt,
Troii
Hall,
Cindy
Sommers,
Scott D.
Hauser,
Jennifer L.
Pierce,
Rodney G.
Combs,
Beverly A.
Reitz,
Judy A.
Diaz-Collier,
Robin A.
Weinberg,
Becky L.
Hood,
Bryan F.
Kilpatrick, and
Catherine S.
Tripp
From Discovery Research, G. D. Searle and Company, the
Monsanto Life Science Company, St. Louis, Missouri 63167
Received for publication, January 12, 2000, and in revised form, May 19, 2000
 |
ABSTRACT |
Nuclear factor kappa B (NF- B) is a ubiquitous,
inducible transcription factor that regulates the initiation and
progression of immune and inflammatory stress responses. NF- B
activation depends on phosphorylation and degradation of its inhibitor
protein, I B, initiated by an I B kinase (IKK) complex. This IKK
complex includes a catalytic heterodimer composed of I B kinase 1 (IKK1) and I B kinase 2 (IKK2) as well as a regulatory adaptor
subunit, NF- B essential modulator. To better understand the role of
IKKs in NF- B activation, we have cloned, expressed, purified, and characterized the physiological isoform, the rhIKK1/rhIKK2 heterodimer. We compared its kinetic properties with those of the homodimers rhIKK1
and rhIKK2 and a constitutively active rhIKK2 (S177E, S181E) mutant. We
demonstrate activation of these recombinantly expressed IKKs by
phosphorylation during expression in a baculoviral system. The
Km values for ATP and I B peptide for the
rhIKK1/rhIKK2 heterodimer are 0.63 and 0.60 µM,
respectively, which are comparable to those of the IKK2 homodimer.
However, the purified rhIKK1/rhIKK2 heterodimer exhibits the highest
catalytic efficiency
(kcat/Km) of 47.50 h 1 µM 1 using an I B
peptide substrate compared with any of the other IKK isoforms,
including rhIKK2 (17.44 h 1
µM 1), its mutant rhIKK2 (S177E, S181E, 1.18 h 1 µM 1), or rhIKK1 (0.02 h 1 µM 1). Kinetic analysis
also indicates that, although both products of the kinase reaction, ADP
and a phosphorylated I B peptide, exhibited competitive inhibitory
kinetics, only ADP with the low Ki of 0.77 µM may play a physiological role in regulation of the
enzyme activity.
 |
INTRODUCTION |
Nuclear factor kappa B
(NF- B)1 is a ubiquitous
transcription factor that plays a prominent role in the activation of
the immune system and in stress responses by regulating the
transcription of many early, inducible genes, including proinflammatory
cytokines, adhesion molecules, growth factors, enzymes, and receptors
(1-3). Specificity of gene expression is determined at a cellular
level by a diverse array of external stimuli such as bacterial
products, including lipopolysaccharide (LPS), as well as cytokines,
most importantly tumor necrosis factor- (TNF ) and interleukin
1 (IL-1 ). Through the synergistic interaction with other
transcription factors, further specificity can be achieved while
maintaining enormous potential to coordinately induce a large number of
functionally related genes. NF- B is composed of homo- and
heterodimers of the Rel protein family and is sequestered in an
inactive form in the cytoplasm by members of the I B family of
inhibitory proteins (1-3). I Bs mask the nuclear localization signal
on NF- B, preventing nuclear translocation and hence DNA binding to
the promoter regions of responsive genes. Stimulation of cells with an
agonist that activates NF- B leads to a series of biochemical
signals, ultimately resulting in the phosphorylation, ubiquitinylation,
and degradation of I Bs, thereby releasing NF- B for nuclear
translocation (1-3). Recently, two I B kinases (IKK1 or IKK and
IKK2 or IKK ), which phosphorylate I Bs and thereby initiate their
degradation, have been cloned and characterized by a number of
laboratories (4-8). The catalytic subunits, IKK1 and IKK2, are similar
structurally as well as enzymatically and exist as a heterodimer in a
large protein complex referred to as the IKK signalsome (4-9). A third protein, NF- B essential modulator (NEMO; IKK , IKKAP1), is a regulatory adapter protein necessary for IKK activation and kinase activity (10-12). IKK1 and IKK2 are coexpressed in most human adult tissues as well as in different developmental stages of mouse embryos
(4-8, 13). This kinase complex appears to represent a critical, common
denominator in the activation of NF- B in a number of signal
transduction pathways stimulated by a variety of agonists, including
cytokines such as TNF and IL-1 , microbial products such as LPS,
and viral proteins such as TAX, as well as phorbol esters, oxidizing
agents, and serine/tyrosine phosphatases (1-3).
IKK1 (also termed IKK ( 4-6)) was cloned simultaneously by standard
biochemical purification of the I B kinase activity from TNF -stimulated HeLa S3 cells and by its interaction with the mitogen-activated protein kinase, NF- B-inducing kinase, in a yeast two-hybrid screen. IKK1 was identified as the previously cloned
serine/threonine kinase, CHUK (14). IKK1 (also termed IKK ) is an
85-kDa, 745-amino acid protein that contains an N-terminal serine/threonine kinase catalytic domain, a leucine zipper-like amphipathic helix, and a C-terminal helix-loop-helix domain. IKK2 (also
termed IKK ) was also cloned by standard biochemical purification, copurifying with IKK1 from TNF -stimulated HeLa S3 cells as well as
by being identified in the public data base from an expressed sequence
tag clone with sequence homology to IKK1 (6-8). IKK2 is an
87-kDa, 756-amino acid protein with the same overall topology as IKK1
except for the addition of an 11-amino acid extension at the C
terminus. IKK1 and IKK2 are 52% identical overall with 65% identity
in the kinase domain and 44% identity in the protein interaction
domains in the C terminus. Data obtained using transient mammalian
expression analysis, by in vitro translation experiments, and by coexpression in a baculoviral system reveal that IKK1 and IKK2
associate preferentially as a heterodimer through their leucine zipper
motifs. Although homodimers have also been described in these systems,
the heterodimer is thought to be the physiological form of the kinase
in mammalian cells (7, 15). Finally, NEMO (also termed IKK ) contains
three -helical regions, including a leucine zipper, interacts
preferentially with IKK2, and is required for activation of the
heterodimeric kinase complex perhaps by bringing other proteins into
the signalsome complex (10-12).
The kinase activities of IKK1 and IKK2 are regulated by phosphorylation
and require an intact leucine zipper for dimerization as well as an
intact helix-loop-helix domain, which can exert a positive regulatory
effect on kinase activity even when it is expressed in trans
with the remainder of the IKK protein (4-8, 16). Both IKK subunits
contain a canonical mitogen activated protein kinase kinase (MAPKK)
activation loop motif near the N terminus, which is the target for
phosphorylation and activation of kinase activity by MAP3Ks such as
NF- B-inducing kinase and MAPK/ERK kinase kinase 1, although the
physiological regulation by these two upstream kinases awaits further
characterization (2-3, 17). Finally, phosphorylation of serines in the
C terminus of IKK2 results in a decreased IKK activity and is
postulated to be responsible for the transient kinase activity seen
after stimulation of cells with an agonist (16).
IKK2 demonstrates a more potent kinase activity compared with IKK1
using I B or I B as a substrate (6-8, 16). Mutations of the
phospho-acceptor serine residues within the MAPKK activation loop
alters IKK2 kinase activity; the serine to alanine substitutions result
in decreased kinase activity, whereas the serine to glutamic acid
substitutions result in a constitutively active kinase. Similar alanine
mutations in IKK1 do not result in a decreased stimulation of total IKK
activity in response to TNF or IL-1 (16). IKK2 being the dominant
kinase activity within the IKK complex is further supported by the
analysis of fibroblasts from mice deficient in IKK1 or IKK2.
Fibroblasts lacking IKK1 retain full IKK activity in response to
cytokines and could activate NF- B. In contrast, fibroblasts lacking
IKK2 do not exhibit IKK activity when stimulated with cytokines nor do
they activate NF- B. Furthermore, the phenotype of each IKK
knock-out is unique, with IKK1 deficiency resulting in skin and
skeletal defects and IKK2 knock-out being embryonic lethal due to
hepatocyte apoptosis (18-22).
The IKK activity has been isolated and characterized from mammalian
cells as well as from expression of recombinant IKK1 and IKK2
homodimers in baculovirus systems (9, 12, 15, 23-27). Both the
isolated IKK complex from mammalian cells and the recombinant IKKs
utilize all three isoforms of I Bs, , , and , as substrates equally well. However, there are differences in the kinetic data reported for the rhIKK homodimers. First, the Km for I B have varied in different publications, with the wide range of
1.4-23 µM being reported for rhIKK1 compared with more
similar values of 0.5-1.3 µM being reported for rhIKK2.
Second, most reports indicate that rhIKK2 phosphorylates truncated
I Bs more efficiently than does rhIKK1 with the
kcat (h 1) being three to four
times greater for rhIKK2 compared with rhIKK1. In addition, the rhIKK2
(S177E, S181E) mutant has a dramatically enhanced kinase activity,
being approximately 10-fold higher than rhIKK2 (12). Third, kinetic
analysis using rhIKK2 also indicates that, in the presence of NF- B,
the Km for I B is decreased from 2.2 to 1.4 µM and the Vmax is increased by a
factor of four, indicating that rhIKK2 phosphorylates I B bound to
NF- B more efficiently than it phosphorylates free I B (16).
Although the physiological form described to be most abundant in
mammalian cells is the IKK1/IKK2 heterodimer, its thorough kinetic
characterization has not been described to date. In this paper we have
characterized the heterodimer rhIKK1/rhIKK2 and compared its kinase
activity to that of the rhIKK1 homodimer rhIKK2 and the mutant rhIKK2
(S177E, S181E) homodimer. Although all purified recombinant enzymes are capable of phosphorylating I B , the rhIKK1/rhIKK2 heterodimer exhibits the highest catalytic efficiency. This kinase activity is
dependent on phosphorylation, because phosphatase treatment abolishes
the ability of each rhIKK to phosphorylate I B . While characterizing the purified rhIKKs, we also found that both of the
products of the kinase reaction, ADP and a phosphorylated I B
peptide, exhibited inhibitory activity; however only ADP has a
Ki that may support a physiological role in the regulation the IKK activity.
While performing these kinetic analysis of rhIKK isoforms, it was noted
that, unlike the IKK activity in mammalian cells, which is not present
unless stimulated by an agonist, the rhIKKs expressed in a baculovirus
system are catalytically active upon their isolation. Because this
signaling pathway is remarkably conserved during evolution, with IKK
activity being described in Drosophila, oysters, and
Dictyostelium (1, 28-29), we propose that recombinantly
expressed hIKKs can be activated by phosphorylation via a homologous
signaling pathway in the baculoviral system. In this paper we also
demonstrate that an anti-NEMO antibody can immunoprecipitate rhIKKs
from insect cell lysates infected with baculovirus containing only
recombinantly expressed IKK proteins, strongly suggesting the presence
of a functional NEMO homologue in the insect cells mediating the
phosphorylation and activation of rhIKKs during expression.
 |
EXPERIMENTAL PROCEDURES |
Materials
Biotin capture plates (SAM2 96) were from Promega.
Anti-FLAG affinity resin, FLAG-peptide, Nonidet P-40, bovine serum
albumin (BSA), ATP, ADP, AMP, LPS (Escherichia coli serotype
0111:B4), and dithiothreitol (DTT) were obtained from Sigma. Antibodies specific for NEMO (IKK ) (FL-419), IKK1(H-744), IKK2(H-470), and I B (C-21) were purchased from Santa Cruz Biotechnology. Ni-NTA resin was purchased from Qiagen. Peptides were purchased from American
Peptide Co. Protease inhibitor mixture tablets were from Roche
Molecular Biochemicals. Sephacryl S-300 column was from Amersham
Pharmacia Biotech. Centriprep-10 concentrators with a molecular
mass cut-off of 10 kDa, and membranes with a molecular mass
cut-off of 30 kDa were obtained from Amicon. [ -33P]ATP
(2500 Ci/mmol) and [ -32P]ATP (6000 Ci/mmol) were
purchased from Amersham Pharmacia Biotech. The other reagents used were
of the highest grade commercially available.
Cloning and Expression
cDNAs of human IKK1 and IKK2 were amplified by reverse
transcriptase-polymerase chain reaction from human placental RNA
(CLONTECH). hIKK1 was subcloned into pFastBac HTa
(Life Technologies) and expressed as N-terminal His6-tagged
fusion protein. The hIKK2 cDNA was amplified using a reverse
oligonucleotide primer that incorporated the peptide sequence for a
FLAG-epitope tag at the C terminus of the IKK2 coding region
(DYKDDDDKD). The hIKK2:FLAG cDNA was subcloned into the baculovirus
vector pFastBac. The rhIKK2 (S177S, E177E) mutant was constructed in
the same vector used for wild type rhIKK2 using a QuikChange
mutagenesis kit (Stratagene). Viral stocks of each construct were used
to infect insect cells grown in suspension culture. The cells were
lysed at a time that maximal expression and rhIKK activity were
demonstrated. Cell lysates were stored at 80 °C until purification
of the recombinant proteins was undertaken as described below.
Enzyme Isolation
All purification procedures were carried out at 4 °C unless
otherwise noted. Buffers used were: buffer A (20 mM
Tris-HCl, pH 7.6, containing 50 mM NaCl, 20 mM
NaF, 20 mM -glycerophosphate, 500 µM
sodium orthovanadate, 2.5 mM metabisulfite, 5 mM benzamidine, 1 mM EDTA, 0.5 mM
EGTA, 10% glycerol, 1 mM DTT, 1× Complete protease inhibitors), buffer B (same as buffer A, except 150 mM
NaCl), and buffer C (same as buffer A, except 500 mM NaCl).
Isolation of rhIKK1 Homodimer--
Cells from an 8-liter
fermentation of baculovirus-expressed IKK1 tagged with His peptide were
centrifuged, and the cell pellet (multiplicity of infection
(m.o.i.) = 0.1; I = 72 h) was resuspended in
100 ml of buffer C. The cells were microfluidized and centrifuged at
100,000 × g for 45 min. The supernatant was collected,
imidazole was added to the final concentration of 10 mM,
and the mixture was incubated with 25 ml of Ni-NTA resin for 2 h.
The suspension was poured into a 25-ml column and washed with 250 ml of
buffer C and then with 125 ml of 50 mM imidazole in buffer
C. The rhIKK1 homodimer was eluted using 300 mM imidazole
in buffer C. BSA and Nonidet P-40 were added to the enzyme fractions to
the final concentration of 0.1%. The enzyme was dialyzed against
buffer B, aliquoted, and stored at 80 °C.
Isolation of rhIKK2 Homodimer and Its Mutant rhIKK2 (S177E,
S181E)--
A 10-liter culture of baculovirus-expressing IKK2 tagged
with FLAG peptide was centrifuged, and the resultant cell pellet (m.o.i. = 0.1; I = 72 h) was resuspended in buffer
A. These cells were microfluidized and centrifuged at 100,000 × g for 45 min. Supernatant was passed over a G-25 column
equilibrated with Buffer A. The protein peak was collected and
incubated with anti-FLAG affinity resin on a rotator overnight in
buffer B. The resin was washed in batch with 10-15 bed volumes of
buffer C. Washed resin was poured into a column, and rhIKK2 homodimer
was eluted using 5 bed volumes of buffer B containing FLAG peptide. A
mixture, 5 mM DTT, 0.1% Nonidet P-40, and BSA,
(concentrated to 0.1% in the final amount) was added to the eluted
enzyme before concentrating in an Amicon membrane with a molecular mass
cut-off of 30 kDa. Enzyme was aliquoted and stored at 80 °C.
rhIKK2 (S177E, S181E) homodimer mutant tagged with FLAG was isolated
following the same method as described above for its wild type.
Isolation of rhIKK1/IKK2 Heterodimer--
The heterodimer enzyme
was produced by coinfection in a baculovirus system (FLAG IKK2/IKK1
His; m.o.i. = 0.1 and I = 72 h). Infected cells
were centrifuged, and the resultant cell pellet (10.0 g) was suspended
in 50 ml of buffer A. The protein suspension was microfluidized and
centrifuged at 100,000 × g for 45 min. Imidazole was
added to the supernatant to a final concentration of 10 mM.
The protein was allowed to bind 25 ml of Ni-NTA resin by mixing for
2 h. The protein-resin slurry was poured into a 25-ml column and
washed with 250 ml of buffer A containing 10 mM imidazole
followed by 125 ml of buffer A containing 50 mM imidazole. Buffer A, containing 300 mM imidazole, was then used to
elute the protein. A 75-ml pool was collected, and Nonidet P-40 was added to a final concentration of 0.1%. The protein solution was then
dialyzed against buffer B. The dialyzed heterodimer enzyme was then
allowed to bind to 25 ml of anti-FLAG M2-agarose affinity gel overnight
with constant mixing. The protein-resin slurry was then centrifuged for
5 min at 2000 rpm. The supernatant was collected, and the resin was
resuspended in 100 ml of buffer C containing 0.1% Nonidet P-40. The
resin was washed with 375 ml of buffer C containing 0.1% Nonidet P-40.
The protein/resin mixture was poured into a 25-ml column, and the
enzyme was eluted using buffer B containing FLAG peptide. Enzyme
fractions (100 ml) were collected and concentrated to 20 ml using an
Amicon membrane with a molecular mass cut-off of 30 kDa. Bovine serum
albumin was added to the concentrated enzyme to final concentration of
0.1%. The enzyme was then aliquoted and stored at 80 °C.
Cell Culture--
The wild type (wt) human pre-B cell line,
70Z/3, and its mutant, 1.3E2, were generously provided by Dr. Carol
Sibley. The wt 70Z/3 and 1.3E2 cells were grown in RPMI 1640 medium
(Life Technologies, Inc.) supplemented with 7% defined bovine serum (Hyclone) and 50 µM 2-mercaptoethanol. Human monocytic
leukemia THP-1 cells, obtained from the ATCC, were cultured in RPMI
1640 supplemented with 10% defined bovine serum, 10 mM
HEPES, 1.0 mM sodium pyruvate, and 50 µM
2-mercaptoethanol. For experiments, cells were plated in 6-well plates
at 1 × 106 cells/ml in fresh media. Pre-B cells were
stimulated by the addition of 10 µg/ml LPS for varying lengths of
time ranging from 0 to 4 h. THP-1 cells were stimulated by the
addition of 1 µg/ml LPS for 45 min. Cells were pelleted, washed with
cold 50 mM sodium phosphate buffer, pH 7.4, containing 0.15 M NaCl, and lysed at 4 °C in 20 mM Hepes
buffer, pH 7.6, containing 50 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM sodium
orthovanadate, 10 mM -glycerophosphate, 1 mM NaF, 1 mM phenylmethylsulfonyl fluoride, 1 mM DTT, and 0.5% Nonidet P-40 (lysis buffer). The
cytosolic fractions obtained following centrifugation at 10,000 × g were stored at 80 °C until use.
Immunoprecipitation and Western Blotting--
Paste from SF9
cells containing rhIKKs was centrifuged (100,000 × g,
10 min) to remove debris. rhIKKs were immunoprecipitated (100 µg of
cell paste) from the cell supernatant using 3 µg of anti-NEMO
antibody (FL-419) followed by coupling to protein A-Sepharose beads.
rhIKKs were also immunoprecipitated from affinity
chromatography-purified protein preparations (1 µg) using anti-FLAG,
anti-His, or anti-NEMO antibodies (1-4 µg) followed by protein
A-Sepharose coupling. The native, human IKK complex was
immunoprecipitated from THP-1 cell homogenates (300 µg/condition)
using the anti-NEMO antibody. Immune complexes were pelleted and washed
three times with 1 ml of cold lysis buffer. Immunoprecipitated rhIKKs
were chromatographed by SDS-polyacrylamide gel electrophoresis (PAGE)
(8% Tris-glycine) and transferred to nitrocellulose membranes (Novex)
and detected by chemiluminescence (SuperSignal) using specific anti-IKK
antibodies (IKK2 H-470, IKK1 H-744). Native IKK2, I B , and NEMO
proteins from cytosolic lysates (20-80 µg) were separated by
SDS-PAGE and visualized by chemiluminescence using specific antibodies.
Phosphatase Treatment--
Immunoprecipitated rhIKKs were washed
two times in 50 mM Tris-HCl, pH 8.2, containing 0.1 mM EDTA, 1 mM DTT, 1 mM
phenylmethylsulfonyl fluoride, and 2 mM MnCl2
and resuspended in 50 µl. PPase (1000 units) was prediluted
in the same buffer and added to the IKK samples. Following an
incubation at room temperature for 30 min with intermittent mixing,
cold lysis buffer was added to the tubes to stop the reaction. After
several washes, 10% of the beads were removed for Western analysis,
and the remaining material was pelleted and resuspended in 100 µl of
the buffer used for the in vitro kinase assay.
Enzyme Assay
Kinase activity was measured using a biotinylated I B
peptide
(Gly-Leu-Lys-Lys-Glu-Arg-Leu-Leu-Asp-Asp-Arg-His-Asp-Ser32-Gly-Leu-Asp-Ser36-Met-Lys-Asp-Glu-Glu),
a SAM2 96 biotin capture plate, and a vacuum system. The
standard reaction mixture contained 5 µM biotinylated
I B peptide, 1 µM [ -33P] ATP (about
1 × 105 cpm), 1 mM DTT, 50 mM
KCl, 2 mM MgCl2, 2 mM
MnCl2, 10 mM NaF, 25 mM Hepes
buffer, pH. 7.6, and enzyme solution (1-10 µl) in a final volume of
50 µl. After incubation at 25 °C for 30 min, 25 µl of the
reaction mixture was withdrawn and added to a SAM2 96 biotin capture 96-well plate. Each well was then washed successively with 800 µl of 2 M NaCl, 1.2 ml of NaCl containing 1%
H3PO4, 400 µl of H2O, and 200 µl of 95% ethanol. The plate was allowed to dry in a hood at
25 °C for 1 h, and then 25 µl of scintillation fluid
(Microscint 20) was added to each well. Incorporation of [ -33P]ATP was measured using a Top-Count NXT
(Packard). Under each assay condition, the degree of phosphorylation of
I B peptide substrate was linear with time and concentration for
all purified enzymes. Results from the biotinylated peptide assay were
confirmed by SDS-PAGE analysis of kinase reaction utilizing a
glutathione S-transferase
(GST)-I B 1-54 fusion protein and
[ -32P]ATP. The resulting radiolabeled substrate was
quantitated using a PhosphorImager (Molecular Dynamics). An ion
exchange resin assay was also employed using [ -33P]ATP
and GST-I B 1-54 fusion protein as the
substrates.2 Each assay
system yielded consistent results in regard to Km and specific activities for each of the purified kinase isoforms. One
unit of enzyme activity was defined as the amount required to catalyze
the transfer of 1 nmol of phosphate from ATP to I B peptide per
minute. Specific activity was expressed as units per milligram of
protein. For experiments related to Km determination of purified enzymes, various concentrations of ATP or I B peptide were used in the assay at a fixed concentration of either I B or
ATP. For I B peptide Km, assays were carried
out with 0.1 µg of enzyme, 5 µM ATP, and I B
peptide from 0.5 to 20 µM. For ATP Km,
assays were carried out with 0.1 µg of enzyme, 10 µM
I B peptide, and ATP from 0.1 to 10 µM. For Km determination of rhIKK1 homodimer, due to its low activity and higher Km for I B peptide, rhIKK1
homodimer (0.3 µg) was assayed with 125 µM I B
peptide and a 5-fold higher specific activity of ATP (from 0.1 to 10 µM) for ATP Km experiments and a
5-fold higher specific activity of 5 µM ATP and I B
peptide (from 5 to 200 µM) for I B peptide
Km experiments.
Other Methods
Protein was hydrolyzed for 24 h in 6 N HCl at
110 °C in vacuo and analyzed on a Beckman 6000 high
performance amino acid analyzer. All analyses were performed after
postcolumn derivatization of the hydrolysates with ninhydrin. Automated
Edman degradation was carried out on an Applied Biosystems model 470 A
protein sequencer as described (30). Protein concentrations were
determined by the method of Bradford (31) or by SDS-PAGE with silver
staining (32) using bovine serum albumin as the standard. Purity and molecular weights of the isolated enzyme were confirmed by SDS-PAGE with silver staining (32).
 |
RESULTS AND DISCUSSION |
Due to its prominent role in NF- B activation, IKKs have been
characterized by many groups. The native IKK complex has been isolated
and biochemically analyzed from mammalian cells (4, 9, 27). In
addition, rhIKK1 and rhIKK2 homodimers from baculovirus expression
systems have been isolated and characterized (16-19). There has been a
discrepancy in kinase activity between native and recombinantly
expressed hIKKs. The native IKK complex did not exhibit kinase activity
unless isolated from cells that had been stimulated by an agonist such
as TNF or IL-1 , but recombinantly expressed hIKKs from
baculovirus systems have kinase activity when purified. The kinase
activity seen with the native IKK complex was dependent on
phosphorylation, because treatment with phosphatase abolished the
kinase activity (5). Thus the IKK complex that was phosphorylated and
activated in mammalian cells could be stably isolated in the presence
of phosphatase inhibitors that prevented dephosphorylation, maintaining
the kinase activity. We propose that this paradigm is also true for the
rhIKKs expressed in a baculovirus system. Recombinant hIKKs when
expressed in a baculovirus system are phosphorylated and require
phosphorylation for their kinase activity, because it is abolished when
these proteins were treated with PPase (Fig.
1A). All of the wild type
rhIKKs have phosphorylation-dependent kinase activity,
whereas the constitutively active mutant rhIKK2 (S177E, S181E) does
not. Phosphatase treatment also results in a shift in mobility of each
wild type rhIKK in SDS-PAGE/Western analysis, but this shift is not as
dramatic for the mutant rhIKK2 (S177E, S181E). Preliminary data maps
the phosphorylation of the rhIKK2 to the MAPKK activation
loop.3 However, the exact
phospho-acceptor sites on each rhIKK are unknown and currently being
determined.

View larger version (56K):
[in this window]
[in a new window]
|
Fig. 1.
Mammalian NEMO is required for endogenous IKK
activation, and a functional NEMO homologue interacts with rhIKKs
overexpressed in a baculovirus system. A, rhIKK
proteins (His6-IKK1 and FLAG-IKK2 homodimers, His6-rhIKK1/FLAG -rhIKK2
heterodimer, and a FLAG -rhIKK-2 (S177E, SS181E) mutant) were
immunoprecipitated using anti-FLAG or anti-His antibodies. The
immunoprecipitated proteins were treated for 30 min with PPase
( ) or heat inactivated PPase ( *) followed by kinase assay or
Western analysis. B, rhIKKs were immunoprecipitated from
crude baculovirus cell paste extracts or from affinity-purified
preparations using an anti-NEMO antibody. rhIKKs were separated by
SDS-PAGE and visualized by Western analysis followed by
chemiluminescence using specific antibodies. Identical results were
seen using the anti-IKK1 antibody for the heterodimer rhIKK1/IKK2.
There were no specific IKK bands detected in either SF9 cell lysates or
in SF9 cell lysates expressing an irrelevant protein following
anti-NEMO immunoprecipitation (data not shown). C, pre-B
cells, 70Z wt and mutant 1.2E3, were plated in 6-well plates and
stimulated with LPS for varying lengths of time ranging from 0 to
4 h. IKK2, I B , and NEMO proteins were separated from
cytosolic lysates by SDS-PAGE and visualized by Western analysis
followed by chemiluminescence using specific antibodies.
|
|
The mechanism by which this IKK phosphorylation and activation occurs
in baculovirus-infected cells is unknown. In mammalian expression
systems, NEMO is required for the activation of IKK. It is thought that
NEMO brings other proteins such as MAP3Ks into the complex to
phosphorylate the IKK catalytic subunits, primarily IKK2 (10-12).
However, data to date have not described a need to coexpress NEMO with
IKK1 and/or IKK2 to obtain kinase activity in baculovirus systems.
Because the NF- B signaling pathway is conserved in evolution (1),
being described in Drosophila, oysters, and
Dictyostelium (1, 28-29), we hypothesized
that an endogenous functional NEMO homologue could function to activate the recombinant IKKs in the insect cells during viral infection. The
role of NEMO in the phosphorylation and activation of native IKK2 is
demonstrated in Fig. 1C. The pre-B cell line, 70Z, has been
shown previously to activate IKK and NF- B in response to LPS,
whereas a mutant line, 1.2E3, does not contain NEMO and cannot activate
NF- B (10). Here we verify that NEMO can be detected by Western
analysis in the 70Z line but not the mutant line, 1.2E3. Likewise, IKK
can be phosphorylated and activated by LPS in the 70Z cells as
demonstrated by a slower migrating band on IKK2 Western analysis (Fig.
1C). The kinetics of IKK2 phosphorylation and activation match the degradation of endogenous I B substrate. Note that, in
the NEMO-deficient cells, neither IKK activation (gel shift) nor
degradation of I B occurs in the presence of LPS. Next, using the
anti-NEMO antibody, we could precipitate active, phosphorylated rhIKK2
from the crude insect cell lysate but not from the affinity-purified rhIKK2 preparation (Fig. 1B). Similar data were generated
with baculovirus cell lysates containing rhIKK1 and rhIKK1/rhIKK2
heterodimer. However, other proteins overexpressed in the baculovirus
system could not be immunoprecipitated using the anti-NEMO antibody; hence, this is not a nonspecific interaction (data not shown). These
data strongly suggest that a functional NEMO homologue from the insect
cells binds to the rhIKKs similar to the mammalian NEMO described in
the signalsome complex (5). We were unable to identify the functional
NEMO homologue by Western blot in crude baculovirus cell lysates with
this antibody. The anti-NEMO antibody could be used to precipitate all
of the rhIKKs, including rhIKK1, which is thought not to bind NEMO in
mammalian cells (data not shown). Note, rhIKK1 is also phosphorylated
during expression in the baculovirus system and this phosphorylation is
required for its kinase activity as well (Fig. 1A). We did
not detect phosphorylation of IKK1 isolated from mammalian cells
stimulated with cytokines using the same methodology (data not shown).
Thus there appears to be a difference in the regulation of IKK1 when
overexpressed during the viral infection in the baculovirus system
compared with endogenous IKK1 from stimulated mammalian cells.
Nevertheless, these data indicate that the activated rhIKKs expressed
and purified from the baculovirus system are phosphorylated during
their expression in a similar manner as described for mammalian IKKs
isolated from cytokine-stimulated cells. Once the phosphorylation of
rhIKKs has occurred during expression, this activity can be preserved using the appropriate phosphatase inhibitors during the purification process, also similar to what is observed from mammalian expression.
Previously, many laboratories have expressed and characterized rhIKK1
and rhIKK2 homodimers, and these studies have produced varying kinetic
results. Although IKK prefers heterodimer formation in both mammalian
cells and when expressed in a baculovirus system, the kinetic
properties of the purified, physiological IKK1/IKK2 heterodimer remain
poorly described (7-9, 15). Here we have characterized the
rhIKK1/rhIKK2 heterodimer isolated from coexpression in a baculovirus
system. The purification procedure of each rhIKK consisted of a
combination of buffer extraction, gel filtration, and affinity
chromatography. rhIKK1 homodimer and rhIKK2 homodimer and its mutant
rhIKK2 (S177E, S181E) were isolated to homogeneity as single bands on
SDS-PAGE analysis (Fig. 2B)
and found predominantly to be dimers by gel filtration analysis (data
not shown). As expected, the purified rhIKK1/rhIKK2 heterodimer
exhibited equal amounts of rhIKK1 and rhIKK2 by SDS-PAGE analysis (Fig.
2, A and B). Note that sequential affinity column
chromatography was necessary to isolate rhIKK1/rhIKK2 heterodimers from
each of the rhIKK1 and rhIKK2 homodimers produced during expression
(Fig. 2A). Similar to other kinases, the rhIKKs exhibited a
narrow pH optimum centered around 7.6. All purified rhIKKs were stable
at 80 °C for at least 3 months in buffer containing 0.1% BSA,
0.1% Nonidet P-40, 10% glycerol, 5 mM DTT, and protease
inhibitors.

View larger version (61K):
[in this window]
[in a new window]
|
Fig. 2.
Characterization of rhIKK isoforms.
A, silver-stained SDS-PAGE and Western analysis of
rhIKK1/rhIKK2 heterodimer. Lane 1, molecular mass standards;
lane 2, Ni-NTA column flow-through fraction; lane
3, Ni-NTA column with 10 mM imidazole wash; lane
4, Ni-NTA column with 30 mM imidazole wash; lane
5, FLAG column flow-through fraction; lane 6, FLAG
column with wash #1; lane 7, FLAG column with wash #2;
lane 8, FLAG column with wash # 3 and lane 9,
FLAG column wash with FLAG peptide. B, silver-stained
SDS-PAGE analysis of purified, rhIKK isoforms: lane 1,
molecular mass standards; lane 2, purified rhIKK1
homodimer; lane 3, purified rhIKK1/rhIKK2 heterodimer;
lane 4, purified rhIKK2 homodimer; and lane 5,
purified rhIKK2 (S177E, S181E) mutant. C, comparison of the
specific activities of purified rhIKKs. As indicated: rhIKK1 homodimer
( ); rhIKK2 (S177E, S181E) ( ); rhIKK2 homodimer ( ); and
rhIKK1/rhIKK2 heterodimer ( ).
|
|
The kinetic properties of the rhIKK1/rhIKK2 heterodimer are compared
with those of the rhIKK1 homodimer, rhIKK2 homodimer, and rhIKK2
(S177E, S181E) in Fig. 2C and in Table
I. The kinetic parameters of purified
rhIKKs were determined using biotinylated I B peptide and
SAM2 96 biotin capture plates as described under
"Experimental Procedures" and recently reported by Wisniewski
et al. (24). These authors demonstrated similar results
using either a biotinylated I B peptide or
GST-I B 1-54 fusion protein. Our results reported here
support their findings that the streptavidin capture assay has a wide
dynamic range, has a high signal-to-background ratio, and is much
quicker and more quantitative than analysis of protein phosphorylation
using the SDS-PAGE assay. Furthermore, the phosphorylation of the
22-amino acid I B consensus peptide or a
GST-I B 1-54 fusion protein by purified rhIKKs
reported herein was specific for Ser32 and
Ser36, because there was no phosphorylation of either
substrate in which the Ser32 and Ser36 were
replaced by Ala (data not shown). Likewise, an irrelevant peptide,
which is phosphorylated by p38 kinase, was not phosphorylated by the
rhIKKs (data not shown).
The rhIKK1/rhIKK2 heterodimer has similar specific activity to the
rhIKK2 homodimer (Fig. 2C). These data support similar findings when IKKs are overexpressed in mammalian cells in that the
activation of IKK2 is responsible of the majority of the total kinase
activity (16). Because the purified rhIKK1/rhIKK2 heterodimer produced
by coexpression is highly active (Fig. 2 and Table I) compared with a
lack of enhanced kinase activity from mixing rhIKK1 and rhIKK2 at
equimolar concentrations after purification (15), it is reasonable to
suggest that, during expression in insect cells, correct folding occurs
between the rhIKK subunits, which results in higher kinase activity.
Results from Fig. 2C also indicated that our specific
activity for rhIKK1 homodimer (about 0.1 nmol/min/mg) is in reasonable agreement with that for rhIKK1 homodimer (0.15 nmol/min/mg of protein)
reported by Mercurio et al. (16). It is interesting that,
although the rhIKK1 is phosphorylated and that the kinase activity is
dependent on this phosphorylation, the specific activity is still very
low. These data support previous findings that IKK1 is not necessary
for NF- B activation in fibroblasts isolated from IKK1-deficient mice
and that the phenotype of the IKK1 knock-out mice is unique compared
with the IKK2-deficient mice. This suggests that this kinase has a
unique function or that a unique substrate other than I B yields a
higher specific activity for IKK1.
Our values for the rhIKK2 homodimer and its constitutive mutant rhIKK2
(S177E, S181E) were significantly different from those previously
reported by Mercurio et al. (12) but similar to those reported for rhIKK2 by Li et al. (15). Although the specific activity of our purified rhIKK2 homodimer was at least 5-fold higher
than that reported by Mercurio et al. (3.2 nmol/min/mg of
protein compared with 0.62 nmol/min/mg (16), our mutant rhIKK2 (S177E,
S181E) displayed 10-fold lower specific activity than their expressed
kinase (0.63 nmol/min/mg of protein compared with 6.5 nmol/min/mg).
Again, the expression conditions resulting in post-translational
modifications such as phosphorylation could explain these
differences, because phosphorylation both positively and negatively
regulates the IKK kinase activity (16). We optimized our expression
conditions to maximize specific activity rather than protein expression.
A comparison of the kinetic parameters (Km and
kcat) for ATP and I B peptide of the
purified rhIKKs with those from other published results are also
summarized in Table I. Note that the Km values for
each substrate for the rhIKK1/rhIKK2 heterodimer are comparable to
those of the rhIKK2 homodimer. The Km values
previously reported for rhIKKs for ATP and for I B are shown for
comparison. Despite different enzyme assays having been used, these
values are in good agreement with each another and with our data (12,
15, 23, 24, 26). The Km values for ATP of purified
rhIKKs are lower that those of other protein kinases such as p38 kinase
(Km = 23.0 µM) and
cAMP-dependent protein kinase (Km = 10.0 µM) (33, 34). It is of interest that the native IKK
complex isolated from HeLa S3 cells using a two-step purification
procedure exhibited a very low dissociation constant for ATP
(KATP of 0.05 µM), as calculated
by fitting the two substrate kinetics to a random sequential model (9).
This finding is not surprising, because other component(s) in the IKK
complex might induce conformational changes in the kinases such that
substrate binding pockets become more accessible to the substrates.
For the apparent maximal turnover kcat, our
value of 3.10 h 1 for the purified rhIKK2 (S177E, S181E)
homodimer is rather low in comparison to the published value of 33.8 h 1 from Mercurio et al. (16) (Table I).
However, our kcat for the rhIKK2 homodimer is at
least 4-fold greater than that for rhIKK2 homodimer reported by
Mercurio et al. (16). Because different kinase assays have
been used among various laboratories, we determined Km and kcat values of
purified rhIKK2 homodimer and rhIKK1/rhIKK2 heterodimer by an
ion-exchange resin-based assay2 as well. The
Km values for ATP of rhIKK2 and rhIKK1/rhIKK2 were
2.61 ± 0.70 and 0.63 ± 0.51 µM,
respectively.2 The Km values for
I B peptides of rhIKK2 and rhIKK1/rhIKK2 were 3.10 ± 1.53 and 0.60 ± 0.03 µM, respectively.2
However, using this kinase assay, the kcat
values of rhIKK2 and rhIKK1/rhIKK2 were slightly lower at 8.6 ± 0.87 h 1 and 11.3 ± 1.31 h 1,
respectively.2 Thus, the difference in
Km and kcat values of
purified rhIKKs from different groups may reflect differences in both
the assay conditions as well as differences in the state of kinase activation by phosphorylation obtained from different expression conditions of each of the rhIKKs. In any case, data from Table I
suggest that, although all four purified rhIKK enzymes are capable of
phosphorylating I B peptide, the catalytic efficiency (kcat/Km) for the I B
peptide of rhIKK1/rhIKK2 heterodimer shows 2.7- and 2375-fold
preference (47.5 h 1 µM 1)
compared with either rhIKK2 homodimer (17.44 h 1
µM 1) or rhIKK1 homodimer (0.02 h 1 µM 1), respectively. These
data are in agreement with the heterodimeric isoform being the
physiological IKK. This increase in catalytic efficiency of the
rhIKK1/rhIKK2 heterodimer compared with the rhIKK2 homodimer may also
be the result of a differential regulation during expression and
activation as a result of the presence of IKK1 in the complex, because
mixing the isolated rhIKK subunits after expression did not yield an
increase in catalytic efficiency.
During the characterization of the rhIKKs, we found that ADP strongly
inhibited all isoforms with
IC50 values in the range of 1.17 to 1.77 µM
(Table II and Fig.
3). This inhibition is selective for ADP,
because AMP shows a markedly decreased ability to inhibit rhIKK1/rhIKK2
heterodimer (Fig. 3A). Note that the other product of the
kinase reaction, an I B peptide phosphorylated at
Ser32 and Ser36
(Gly-Leu-Lys-Lys-Glu-Arg-Leu-Leu-Asp-Asp-Arg-His-Asp-Ser·PO3H2-Gly-Leu-Asp-Ser·PO3H2-Met-Lys-Asp-Glu-Glu), is not as effective at inhibiting rhIKK1/rhIKK2 as ADP is. Also, both
products of the kinase reaction inhibit native IKK complex purified
from mammalian cells similarly to rhIKK1/rhIKK2 but again, ADP is a far
more effective inhibitor than the phosphorylated I B peptide (Fig.
3B). Kinetic analysis shows that ADP competitively inhibits
rhIKK1/rhIKK2 heterodimer with respect to ATP (Ki value of 0.77 µM) and noncompetitively inhibits this
kinase with respect to I B peptide (Ki value of
1.08 µM, Fig. 4). ADP does
not inhibit p38 kinase and or c-Jun N-terminal
kinase 2 in this concentration
range,4 most likely because
the Km for ATP for p38 kinase is so much higher than
the IKKs. In the preparation of this manuscript, Peet and Li (26)
reported the competitive inhibition by ADP of both the rhIKK1 and
rhIKK2 homodimeric isoforms with similar Ki values
of 0.15 µM as reported here. Thus, these data herein
extend the observation to include the inhibition of the recombinant
heterodimer and the mammalian IKK complex by ADP and support a
potential physiological role for ADP in the feedback inhibition of
endogenous IKK activity. Also the Ki for ADP is not
significantly changed as a result of dimerization of the two IKK
subunits. To gain more insight regarding the ATP site, the effect of
various ADP analogues on rhIKK activities were also examined. As shown
in Table II, many ADP analogues, including adenosine
5'-O-(3-thiotriphosphate), adenosine 5'-phosphosulfate, , -methyleneadenosine 5'triphosphate,
2'-&3'-O-(4-benzoyl)adenosine 5'-triphosphate,
adenosine 5'-triphosphate,
r-(1-(2-nitrophenyl)ethyl)ester, and cordycepin
5'-triphosphate strongly inhibit all recombinant IKK isoforms. Among
these analogues, , -methyleneadenosine 5'triphosphate and
adenosine 5'-O-(3-thiodiphosphate) are the strongest
inhibitors with IC50 values of 1.00 and 2.15 µM, respectively, and are comparable to ADP. However, no
selectivity between rhIKK isoforms was identified with these compounds,
indicating that the ATP sites in rhIKK1 and rhIKK2 are similar. This is
not surprising, because these ADP analogs are relatively small
compounds and the kinase sites are 65% homologous between the rhIKK1
and rhIKK2 isoforms. Note that many ADP analogs demonstrated no
inhibition similar to AMP, thus defining some structural selectivity.
Structural differences at this site, however, will no doubt be revealed
once the crystal structures are solved. Further characterization of the
rhIKK1/rhIKK2 heterodimer also indicates that the phosphorylated
I B peptide competitively inhibits kinase activity with respect to
I B (Ki value of 263.74 µM) and
noncompetitively inhibits the heterodimer with respect to ADP (Fig. 4).
Similarly, Peet and Li (26) demonstrated that a nonphosphorylated
I B peptide competitively inhibited rhIKK1 and rhIKK2 at the I B
site with Ki values of 139 and 90 µM, respectively. Thus, our results demonstrate that even
a phosphorylated form of consensus I B peptide will not compete as
well as ADP does at its site. These data suggest that, of the two
products of the kinase reaction, ADP may significantly contribute to
feedback inhibition of kinase activity in vivo. Inhibition
by ADP could inhibit IKK in cellular situations where ATP reserves are
low, given the fact that NF- B, along with heat shock proteins, are the paradigm for stress response transcription factors. However, this
is also dependent on the cellular concentration of phosphorylated I B and whether the Ki for each phosphorylated
I B isoform would be lower when complexed with NF- B, as reported
for the Km of I B (23).

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 3.
Effects of the kinase products on activity of
rhIKK1/rhIKK2 heterodimer (A) and on the activity of
native IKK complex (B). IKK complex
immunoprecipitated from LPS induced THP-1 monocytes using anti-NEMO
antibody. ADP ( ), phosphorylated I B peptide ( ), and AMP
( ) were incubated with rhIKK1/rhIKK2 or native IKK complex, and
kinase activities were measured as described under "Experimental
Procedures." Similar effects of ADP, phosphorylated I B peptide
and AMP on IKK2 homodimer, rhIKK1 homodimer, and rhIKK2 (S177E, S181E)
were seen (data not shown).
|
|

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 4.
Inhibition by ADP and phosphorylated
I B peptide on
rhIKK1/rhIKK2 heterodimer kinase activity. Competitive
(A) and noncompetitive (B) inhibition of ADP on
rhIKK1/rhIKK2 heterodimer kinase activity with respect to ATP and
I B peptide, respectively. Competitive (C) and
noncompetitive (D) inhibition of phosphorylated I B
peptide on rhIKK1/rhIKK2 heterodimer kinase activity with respect to
I B peptide and ATP, respectively. Concentration of inhibitors
used were: (A and B) ADP: 0 ( ), 0.4 ( ), 1.0 ( ), and 2.0 µM ( ) and (C and
D) phosphorylated I B peptide: 0 ( ), 0.5 ( ), 1.0 ( ), and 2.0 mM ( ). A similar pattern of inhibition
was demonstrated for rhIKK2 homodimer, rhIKK1 homodimer, and rhIKK2
(S177E, S181E) mutant by ADP and phosphorylated I B peptide (data
not shown). Ki values (in the text) were determined
as described by Leatherbarrow (35).
|
|
In summary, in the present study we have expressed, purified, and
characterized the physiological form of the IKK kinase complex, the
rhIKK1/rhIKK2 heterodimer, and compared its kinetic parameters with
those of the rhIKK1 homodimer, rhIKK2 homodimer, and rhIKK2 (S177E,
S181E) mutant. The rhIKK1/rhIKK2 heterodimer exhibits the highest
catalytic efficiency toward I B -truncated substrates, supporting
the current hypothesis that this is the physiological isoform found in
the IKK signalsome. Although these purified rhIKKs are inhibited by
both of their kinase products, ADP and phosphorylated I B peptide,
ADP by virtue of its low Ki may play a role in
regulating kinase activity in vivo. Inhibition of IKK activity by ADP contributes mechanistically both to the transient kinase activity and NF- B activation demonstrated in cells.
Furthermore, the rhIKKs expressed in a baculovirus system are activated
by phosphorylation most likely via a homologous signaling pathway in
insect cells, which is activated by viral infection similarly to
mammalian cells. Thus the characterization of activated IKKs is
facilitated by this apparent conservation of the NF- B signaling pathway.
 |
ACKNOWLEDGEMENTS |
We thank Drs. William M. Moore and Joseph B. Monahan for helpful suggestions. We also thank Kuniko K. Kretzmer, Wei
Liao, Michael G. Jennings, James F. Zobel, Erwin Yu, Lori J. Christine, Gary W. Lange, Robert P. Compton, and Jeffrey L. Hirsch for
their support with enzyme assays, cell culture, gene cloning,
expression, isolation, and analysis of the rhIKKs.
 |
FOOTNOTES |
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of Discovery
Pharmacology, Searle Discovery Research, c/o Monsanto Life Science
Company, Mailzone T3M, 800 North Lindbergh Blvd., St. Louis, MO 63167. Tel.: 314-694-5360; Fax: 314-694-3415; E-mail: quang.k.huynh@monsanto.com.
Published, JBC Papers in Press, May 22, 2000, DOI 10.1074/jbc.M000296200
2
Q. K. Huynh, H. Boddupalli, C. M. Koboldt, B. L. Hood, B. F. Kilpatrick, and C. S. Tripp,
unpublished data.
3
G. W. Lange, unpublished data.
4
R. P. Compton and J. L. Hirsch,
unpublished data.
 |
ABBREVIATIONS |
The abbreviations used are:
NF- B, nuclear
factor kappa B;
IKK, I B kinase;
IKK2 (S177E, S181E), a variant of
IKK2 in which Ser177 and Ser181 are replaced by
Glu;
TNF, tumor necrosis factor;
LPS, lipopolysaccharide;
NEMO, NF- B
essential modulator;
ERK, extracellular signal-regulated kinase;
IKKAP1, IKK complex-associated protein 1;
MAPK, mitogen-activated
protein kinase;
rh, recombinant human;
wt, wild type;
DTT, dithiothreitol;
PAGE, polyacrylamide gel electrophoresis;
m.o.i., multiplicity of infection;
IL-1 , interleukin 1 ;
BSA, bovine serum
albumin;
GST, glutathione S-transferase;
PPase, recombinant protein phosphatase.
 |
REFERENCES |
| 1.
|
Ghosh, S.,
May, M. J.,
and Kopp, E.
(1998)
Annu. Rev. Immunol.
16,
115-260
|
| 2.
|
Zandi, E.,
and Karin, M.
(1999)
Mol. Cell. Biol.
19,
4547-4551
|
| 3.
|
Karin, M.
(1999)
J. Biol. Chem.
274,
27339-27342
|
| 4.
|
Regnier, C.,
Song, H.,
Gao, X.,
Goeddel, D.,
Cao, Z.,
and Rothe, M.
(1997)
Cell
90,
373-383
|
| 5.
|
DiDonato, J. A.,
Hayakawa, M.,
Rothwarf, D. M.,
Zandi, E.,
and Karin, M.
(1997)
Nature
388,
548-554
|
| 6.
|
Mercurio, F.,
Zhu, H.,
Murray, B. W.,
Shevchenko, A.,
Bennett, B. L.,
Li, J. W.,
Young, D. B.,
Barbosa, M.,
Mann, M.,
Manning, A.,
and Roa, A.
(1997)
Science
278,
860-866
|
| 7.
|
Zandi, E.,
Rothwarf, D. M.,
Delhase, M.,
Hayadawa, M.,
and Karin, M.
(1997)
Cell
91,
243-252
|
| 8.
|
Woronicz, J. D.,
Gao, X.,
Cao, Z.,
Rothe, M.,
and Goeddel, D. V.
(1997)
Science
278,
866-869
|
| 9.
|
Burke, J.,
Miller, K.,
Wood, M.,
and Meyers, C.
(1998)
J. Biol. Chem.
273,
12041-12046
|
| 10.
|
Yamaoka, S.,
Courtois, G.,
Bessia, C.,
Whiteside, S. T.,
Weil, R.,
Agou, F.,
Kirk, H. E.,
Kay, R. J.,
and Ireal, A.
(1998)
Cell
93,
1231-1240
|
| 11.
|
Rothwarf, D. M.,
Zandi, E.,
Natoli, G.,
and Karin, M.
(1998)
Nature
395,
297-300
|
| 12.
|
Mercurio, F.,
Murray, B. W.,
Shevchenko, A.,
Bennet, B. L.,
Young, D. B.,
Li, J. W.,
Pascual, G.,
Motiwala, A.,
Zhu, H.,
Mann, M.,
and Manning, A. M.
(1999)
Mol. Cell. Biol.
2,
1526-1538
|
| 13.
|
Hu, M. C. T.,
and Wang, Y.
(1998)
Gene
222,
31-40
|
| 14.
|
Connelly, M.,
and Marcu, K.
(1995)
Cell. Mol. Biol. Res.
41,
537-549
|
| 15.
|
Li, J.,
Peet, G. W.,
Pullen, S. S.,
Schembri-King, J.,
Warren, T. C.,
Marcu, K. B.,
Kehry, M. R.,
Barton, R.,
and Jakes, S.
(1998)
J. Biol. Chem.
273,
30736-30741
|
| 16.
|
Delhase, M.,
Hayakawa, M.,
Chen, Y.,
and Karin, M.
(1999)
Science
284,
309-313
|
| 17.
|
Karin, M.,
and Delhase, M.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
9067-9069
|
| 18.
|
Li, Q.,
Antwerp, D. V.,
Mercurio, F.,
Lee, K.,
and Verma, I. M.
(1999)
Science
284,
321-325
|
| 19.
|
Takeda, K.,
Tekeuchi, O.,
Tsujimura, T.,
Itami, S.,
Adachi, O.,
Kawai, T.,
Sanjo, H.,
Yoshikawa, K.,
Terada, N.,
and Akira, S.
(1999)
Science
284,
313-316
|
| 20.
|
Hu, Y.,
Baud, V.,
Delhase, M.,
Zhang, P.,
Deerinck, T.,
Ellisman, M.,
Johnson, R.,
and Karin, M.
(1999)
Science
284,
315-320
|
| 21.
|
Li, Q.,
Lu, Q.,
Hwang, J. Y.,
Buscher, D.,
Lee, K.,
Izpisua-Belmonte, J. C.,
and Verma, I. M.
(1999)
Genes Dev.
13,
1322-1328
|
| 22.
|
Tanaka, M.,
Fuentes, M. E.,
Yamaguchi, K.,
Durnin, M. H.,
Dalrymple, S. A.,
Hardy, K. L.,
and Goeddel, D. V.
(1999)
Immunity
10,
421-429
|
| 23.
|
Zandi, E.,
Chen, Y.,
and Karin, M.
(1998)
Science
281,
1360-1363
|
| 24.
|
Wisniewski, D.,
LoGrasso, P.,
Calaycay, J.,
and Marcy, A.
(1999)
Anal. Biochem.
274,
220-228
|
| 25.
|
Heilker, R.,
Freuler, F.,
Pulfer, R.,
Padova, F. D.,
and Eder, J.
(1999)
Eur. J. Biochem.
259,
253-261
|
| 26.
|
Peet, G. W.,
and Li, J.
(1999)
J. Biol. Chem.
274,
32655-32661
|
| 27.
|
Heilker, R.,
Freuler, F.,
Vanek, M.,
Pulfer, R.,
Kobel, T.,
Peter, J.,
Zerwes, H.,
Hofstetter, H.,
and Eder, J.
(1999)
Biochemistry
38,
6231-6238
|
| 28.
|
Escoubas, J.,
Briant, L.,
Montagnani, C.,
Hez, S.,
Deveaux, C.,
and Roch, P.
(1999)
FEBS Lett.
453,
293-298
|
| 29.
|
Traincard, F.,
Ponte, E.,
Pun, J.,
Coukell, B.,
and Veron, M.
(1999)
J. Cell Sci.
112,
3529-3535
|
| 30.
|
Hunkapiller, M. W.,
Hewick, R. M.,
Dreyer, W. J.,
and Hood, L. E.
(1983)
Methods Enzymol.
91,
399-413
|
| 31.
|
Bradford, M. M.
(1986)
Anal. Biochem.
72,
248-254
|
| 32.
|
Laemmli, U. K.
(1970)
Nature
227,
680-685
|
| 33.
|
Bhatnagar, D.,
Roskoski, R. J.,
Rosendahl, M. S.,
and Leonard, N. J.
(1983)
Biochemistry
22,
6310-6317
|
| 34.
|
LoGrasso, P. V.,
Frantz, B.,
Rolando, A. M.,
O'Keefe, S. J.,
Hermes, J. D.,
and O'Neil, E. A.
(1997)
Biochemistry
36,
10422-10427
|
| 35.
|
Leatherbarrow, R. J.
(1992)
Grafit, version 4.0
, Erithacus Software Ltd., Staines, UK
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
J.-P. Guo, S.-K. Shu, L. He, Y.-C. Lee, P. A. Kruk, S. Grenman, S. V. Nicosia, G. Mor, M. J. Schell, D. Coppola, et al.
Deregulation of IKBKE Is Associated with Tumor Progression, Poor Prognosis, and Cisplatin Resistance in Ovarian Cancer
Am. J. Pathol.,
July 1, 2009;
175(1):
324 - 333.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Kawauchi, K. Araki, K. Tobiume, and N. Tanaka
Loss of p53 enhances catalytic activity of IKK{beta} through O-linked {beta}-N-acetyl glucosamine modification
PNAS,
March 3, 2009;
106(9):
3431 - 3436.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Van Gammeren, J. S. Damrauer, R. W. Jackman, and S. C. Kandarian
The I{kappa}B kinases IKK{alpha} and IKK{beta} are necessary and sufficient for skeletal muscle atrophy
FASEB J,
February 1, 2009;
23(2):
362 - 370.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. T. Lam, R. E. Davis, V. N. Ngo, G. Lenz, G. Wright, W. Xu, H. Zhao, X. Yu, L. Dang, and L. M. Staudt
Compensatory IKK{alpha} activation of classical NF-{kappa}B signaling during IKK{beta} inhibition identified by an RNA interference sensitization screen
PNAS,
December 30, 2008;
105(52):
20798 - 20803.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. L. Austin, A. Rune, K. Bouzakri, J. R. Zierath, and A. Krook
siRNA-Mediated Reduction of Inhibitor of Nuclear Factor-{kappa}B Kinase Prevents Tumor Necrosis Factor-{alpha}-Induced Insulin Resistance in Human Skeletal Muscle
Diabetes,
August 1, 2008;
57(8):
2066 - 2073.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. W. Hansberger, J. A. Campbell, P. Danthi, P. Arrate, K. N. Pennington, K. B. Marcu, D. W. Ballard, and T. S. Dermody
I{kappa}B Kinase Subunits {alpha} and {gamma} Are Required for Activation of NF-{kappa}B and Induction of Apoptosis by Mammalian Reovirus
J. Virol.,
February 1, 2007;
81(3):
1360 - 1371.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Schomer-Miller, T. Higashimoto, Y.-K. Lee, and E. Zandi
Regulation of I{kappa}B Kinase (IKK) Complex by IKK{gamma}-dependent Phosphorylation of the T-loop and C Terminus of IKKbeta
J. Biol. Chem.,
June 2, 2006;
281(22):
15268 - 15276.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Hai, M.-L. Yeung, T. G. Wood, Y. Wei, S. Yamaoka, Z. Gatalica, K.-T. Jeang, and A. R. Brasier
An Alternative Splice Product of I{kappa}B Kinase (IKK{gamma}), IKK{gamma}-{Delta}, Differentially Mediates Cytokine and Human T-Cell Leukemia Virus Type 1 Tax-Induced NF-{kappa}B Activation
J. Virol.,
May 1, 2006;
80(9):
4227 - 4241.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S.-J. Jeong, C. A. Pise-Masison, M. F. Radonovich, H. U. Park, and J. N. Brady
A Novel NF-{kappa}B Pathway Involving IKK{beta} and p65/RelA Ser-536 Phosphorylation Results in p53 Inhibition in the Absence of NF-{kappa}B Transcriptional Activity
J. Biol. Chem.,
March 18, 2005;
280(11):
10326 - 10332.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. S. Hayden and S. Ghosh
Signaling to NF-{kappa}B
Genes & Dev.,
September 15, 2004;
18(18):
2195 - 2224.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. B. DeMeritt, L. E. Milford, and A. D. Yurochko
Activation of the NF-{kappa}B Pathway in Human Cytomegalovirus-Infected Cells Is Necessary for Efficient Transactivation of the Major Immediate-Early Promoter
J. Virol.,
May 1, 2004;
78(9):
4498 - 4507.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Kishore, C. Sommers, S. Mathialagan, J. Guzova, M. Yao, S. Hauser, K. Huynh, S. Bonar, C. Mielke, L. Albee, et al.
A Selective IKK-2 Inhibitor Blocks NF-{kappa}B-dependent Gene Expression in Interleukin-1{beta}-stimulated Synovial Fibroblasts
J. Biol. Chem.,
August 29, 2003;
278(35):
32861 - 32871.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. R. Burke, M. A. Pattoli, K. R. Gregor, P. J. Brassil, J. F. MacMaster, K. W. McIntyre, X. Yang, V. S. Iotzova, W. Clarke, J. Strnad, et al.
BMS-345541 Is a Highly Selective Inhibitor of Ikappa B Kinase That Binds at an Allosteric Site of the Enzyme and Blocks NF-kappa B-dependent Transcription in Mice
J. Biol. Chem.,
January 10, 2003;
278(3):
1450 - 1456.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Kishore, Q. K. Huynh, S. Mathialagan, T. Hall, S. Rouw, D. Creely, G. Lange, J. Caroll, B. Reitz, A. Donnelly, et al.
IKK-i and TBK-1 are Enzymatically Distinct from the Homologous Enzyme IKK-2. COMPARATIVE ANALYSIS OF RECOMBINANT HUMAN IKK-i, TBK-1, AND IKK-2
J. Biol. Chem.,
April 12, 2002;
277(16):
13840 - 13847.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q. K. Huynh, N. Kishore, S. Mathialagan, A. M. Donnelly, and C. S. Tripp
Kinetic Mechanisms of Ikappa B-related Kinases (IKK) Inducible IKK and TBK-1 Differ from IKK-1/IKK-2 Heterodimer
J. Biol. Chem.,
April 5, 2002;
277(15):
12550 - 12558.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. S. Miller and E. Zandi
Complete Reconstitution of Human Ikappa B Kinase (IKK) Complex in Yeast. ASSESSMENT OF ITS STOICHIOMETRY AND THE ROLE OF IKKgamma ON THE COMPLEX ACTIVITY IN THE ABSENCE OF STIMULATION
J. Biol. Chem.,
September 21, 2001;
276(39):
36320 - 36326.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|